Blog
Latest articles, insights, and updates from the blog.
Need help or want to reach readers?
Have a correction, provider question, or advertising inquiry? Reach the editorial team.
FDA Fast-Tracks Psychedelics for Depression, PTSD, and AUD
The FDA is accelerating psychedelic drug development for treatment-resistant depression, PTSD, and AUD. What it means for patients exploring ketamine therapy.
AXS-05 Nears FDA Decision for Alzheimer's Agitation
AXS-05, an oral NMDA-targeting drug, nears FDA approval for Alzheimer's agitation. Here's what it means for the ketamine treatment landscape.
Side Effects & Dropout Rates: New Data on Ketamine for TRD
New clinical guidance on NMDA antagonist side effects and dropout rates offers practical insight for patients considering ketamine therapy for TRD.
Why Patients Quit NMDA Therapy—And What Providers Should Do
New clinical review urges faster dose optimization and earlier switching between NMDA therapies for treatment-resistant depression. Here's what it means for patients.
When to Push for Stronger TRD Treatments, Per Experts
Psychiatric Times highlights underuse of highly effective TRD treatments. Here's what this means if you or a loved one is stuck in a cycle of failed antidepressants.
Trump Signs EO to Speed Psychedelic Research & Access
President Trump signed an executive order accelerating psychedelic research and access in April 2026. Here's what it means for ketamine therapy patients.
NMDA Side Effects: What Dropout Rates Mean for Patients
New clinical guidance on NMDA antagonist side effects and dropout rates offers practical insights for patients considering ketamine or esketamine therapy.
Ketamine Side Effects: What New Clinical Data Reveals
New clinical analysis examines side effect profiles and discontinuation rates for ketamine and esketamine. Here's what treatment-resistant depression patients should know.
NRx's Preservative-Free Ketamine Moves Through FDA Review
NRx Pharmaceuticals reports progress on its FDA application for a preservative-free ketamine formulation. What patients should know about this development.
Psychedelics Executive Order: What It Means for Ketamine Patients
A new executive order targeting psychedelic medicines is reshaping the regulatory landscape. Here's what ketamine therapy patients should understand.
BPL-003 Shows Lasting Relief in Treatment-Resistant Depression
New phase 2a data on BPL-003 shows sustained symptom reduction in treatment-resistant depression. What patients should know about this emerging therapy.
Ketamine Side Effects: What New Data Tells Patients
A new clinical review examines side effect profiles and discontinuation rates for NMDA antagonists like ketamine and esketamine. Here's what patients should know.
Ketamine Side Effects: What New Data Means for Patients
New clinical guidance on NMDA antagonist side effects and discontinuation rates gives patients and families sharper questions to ask before starting ketamine therapy.